Vitrolife AB
STO:VITR
Vitrolife AB
STO:VITR
Price:
181.1 SEK
-1.36%
Market Closed
Updated:
Jun 9, 2024
Vitrolife AB
Cost of Revenue
|
Vitrolife AB
Cost of Revenue Peer Comparison
Comparables:
BIOG B
HNSA
BONEX
SOBI
BIOA B
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vitrolife AB
STO:VITR
|
Cost of Revenue
-kr1.5B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-26%
|
|
|
Biogaia AB
STO:BIOG B
|
Cost of Revenue
-kr346.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Hansa Biopharma AB
STO:HNSA
|
Cost of Revenue
-kr71.7m
|
CAGR 3-Years
-214%
|
CAGR 5-Years
-124%
|
CAGR 10-Years
-63%
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Cost of Revenue
-kr52.4m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Cost of Revenue
-kr5.4B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-19%
|
|
|
BioArctic AB
STO:BIOA B
|
Cost of Revenue
-kr50.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
See Also
What is Vitrolife AB's Cost of Revenue?
Cost of Revenue
-1.5B
SEK
-1.5B
SEK
Based on the financial report for Mar 31, 2024, Vitrolife AB's Cost of Revenue amounts to -1.5B SEK.
What is Vitrolife AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-26%
-26%
Over the last year, the Cost of Revenue growth was -2%. The average annual Cost of Revenue growth rates for Vitrolife AB have been -47% over the past three years , -30% over the past five years , and -26% over the past ten years .
You don't have any saved screeners yet
